ReviewBMC medicine2014
Predicting outcome from dengue.
Review in BMC medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05611710 (Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial), which is not on this map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Predictive markers for the early prognosis of dengue severity: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2021Pooled it
- Post-dengue acute disseminated encephalomyelitis: A case report and meta-analysis.PLoS neglected tropical diseases · 2017Pooled it
- Safety and tolerability of metformin in overweight and obese patients with dengue: An open-label clinical trial (MeDO).PLoS neglected tropical diseases · 2025Trial
- Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Dengue virus infection.Nature reviews. Disease primers · 2026Review
- Improving early prediction for adverse dengue outcomes using data from the IDAMS prospective multicentre study.Nature communications · 2026Observational
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Deep data-independent acquisition-based plasma proteomic profiling unveils distinct molecular features in dengue fever with neutropenia.Virologica Sinica · 2025Article
- Correlation between Dengue Hemorrhagic Fever Severity and Comorbid Conditions in Patients.Journal of pharmacy & bioallied sciences · 2025Article
- Predicting deterioration in dengue using a low cost wearable for continuous clinical monitoring.NPJ digital medicine · 2024Article
- Role of Serum Ferritin as a Predictor of Dengue Severity: A Prospective Observational Study From India.Cureus · 2024Article
- Analysis of Dengue and SARS-CoV-2 Coinfection in a Tertiary Care Hospital: A Retrospective Study.Journal of tropical medicine · 2024Article
- Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial.Wellcome open research · 2024Article
- Mice, myeloid cells, and dengue: a new model for unraveling vascular leakage mysteries.Frontiers in microbiology · 2024Article
- Predictors of Clinically Significant Bleeding in Thrombocytopenic Dengue Patients Admitted to Intensive Care Unit: A Retrospective Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2023Article
- A Multi-Site, Multi-Wavelength PPG Platform for Continuous Non-Invasive Health Monitoring in Hospital Settings.IEEE transactions on biomedical circuits and systems · 2023Article
- Learning meaningful latent space representations for patient risk stratification: Model development and validation for dengue and other acute febrile illness.Frontiers in digital health · 2023Article
- Discovery and validation of circulating miRNAs for the clinical prognosis of severe dengue.PLoS neglected tropical diseases · 2022Article
- Dengue algorithms integrated into the IMCI guidelines: An updated assessment in five Southeast-Asian countries.PLoS neglected tropical diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Dengue is emerging as one of the most abundant vector-borne disease globally. Although the majority of infections are asymptomatic or result in only a brief systemic viral illness, a small proportion of patients develop potentially fatal complications. These severe manifestations, including a unique plasma leakage syndrome, a coagulopathy sometimes accompanied by bleeding, and organ impairment, occur relatively late in the disease course, presenting a window of opportunity to identify the group of patients likely to progress to these complications. However, as yet, differentiating this group from the thousands of milder cases seen each day during outbreaks remains challenging, and simple and inexpensive strategies are urgently needed in order to improve case management and to facilitate appropriate use of limited resources. This review will cover the current understanding of the risk factors associated with poor outcome in dengue. We focus particularly on the clinical features of the disease and on conventional investigations that are usually accessible in mid-level healthcare facilities in endemic areas, and then discuss a variety of viral, immunological and vascular biomarkers that have the potential to improve risk prediction. We conclude with a description of several novel methods of assessing vascular function and intravascular volume status non-invasively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.